))
S1 E8 - Dr Hope Rugo – ESMO 2022 – Exploring the Latest Trial Data and Advances in Breast Cancer Treatments
Manage episode 407348226 series 3559566
Content provided by Karger Publishers. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karger Publishers or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Welcome to the third episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer we speak with Dr Hope Rugo, Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Dr Rugo summarizes the TROPICS02 trial that she presented at this year's conference. We also discuss how data presented from the METEORA and ICON trials add to clinical understandings of immunotherapy response. Coverage is also provided to the ADAPT trial. Finally, we discuss how these clinical improvements in response and progression free survival (PFS) translate to the patient experience.
For additional coverage and conference highlights in Oncology please visit https://www.karger.com/SubjectArea/Oncology/oncology-conference-highlights
For more podcast episodes from Karger please visit https://www.karger.com/podcasts
This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
17 episodes
Share
